Cargando…

Anti-PD-1 antibody armored γδ T cells enhance anti-tumor efficacy in ovarian cancer

γδ T cells have the unique ability to detect a wide range of tumors with low mutation burdens, making them attractive candidates for CAR-T-cell therapy. Unlike αβ T cells and other immune cells, γδ T cells are superior in MHC non-restriction, selective cell recruitment, and rapid activation. However...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Yue, Han, Jingyi, Wang, Dongdong, Cai, Menghua, Xu, Yi, Hu, Yu, Chen, Hui, He, Wei, Zhang, Jianmin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10587135/ https://www.ncbi.nlm.nih.gov/pubmed/37857598 http://dx.doi.org/10.1038/s41392-023-01646-7

Ejemplares similares

Wounding characteristics and treatment principles of ground anti-armored vehicle ammunition against armored crew
por: Li, Yue, et al.
Publicado: (2023)

Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment
por: Yeku, Oladapo O., et al.
Publicado: (2017)

Biomarkers for Predicting Efficacies of Anti-PD1 Antibodies
por: Kambayashi, Yumi, et al.
Publicado: (2019)

The combination therapy of oncolytic HSV-1 armed with anti-PD-1 antibody and IL-12 enhances anti-tumor efficacy
por: Xie, Xin, et al.
Publicado: (2021)

The Use of Laminates of Commercially Available Fabrics for Anti-Stab Body-Armor
por: Khuyen, Nguyen Quang, et al.
Publicado: (2021)

One‐Step Soaking Strategy toward Anti‐Swelling Hydrogels with a Stiff “Armor”
por: Dou, Xueyu, et al.
Publicado: (2023)

Plasticity of γδ T Cells: Impact on the Anti-Tumor Response
por: Lafont, Virginie, et al.
Publicado: (2014)

A novel dominant-negative PD-1 armored anti-CD19 CAR T cell is safe and effective against refractory/relapsed B cell lymphoma
por: Liu, Xiaoqian, et al.
Publicado: (2021)

The Role of Human γδ T Cells in Anti-Tumor Immunity and Their Potential for Cancer Immunotherapy
por: Liu, Yuxia, et al.
Publicado: (2020)

Next generation of anti-PD-L1 Atezolizumab with enhanced anti-tumor efficacy in vivo
por: Li, Maohua, et al.
Publicado: (2021)

Anti-CD40 mAb enhanced efficacy of anti-PD1 against osteosarcoma
por: Zhang, Jingzhe, et al.
Publicado: (2019)

Anti-CD3 Fab Fragments Enhance Tumor Killing by Human γδ T Cells Independent of Nck Recruitment to the γδ T Cell Antigen Receptor
por: Juraske, Claudia, et al.
Publicado: (2018)

Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models
por: Wang, Zebin, et al.
Publicado: (2019)

Local IFNα enhances the anti-tumoral efficacy of systemic anti-PD1 to prevent tumor relapse
por: Guerin, Marion v, et al.
Publicado: (2020)

Weapons & armor
Publicado: (1978)

The Dual Roles of Human γδ T Cells: Anti-Tumor or Tumor-Promoting
por: Li, Yang, et al.
Publicado: (2021)

Monocyte subsets associated with the efficacy of anti‑PD‑1 antibody monotherapy
por: Ohkuma, Ryotaro, et al.
Publicado: (2023)

PD-L1 blockade enhances anti-tumor efficacy of NK cells
por: Oyer, Jeremiah L., et al.
Publicado: (2018)

Combined treatment with anti‐PSMA CAR NK‐92 cell and anti‐PD‐L1 monoclonal antibody enhances the antitumour efficacy against castration‐resistant prostate cancer
por: Wang, Fangming, et al.
Publicado: (2022)

Author Correction: Next generation of anti-PD-L1 Atezolizumab with enhanced anti-tumor efficacy in vivo
por: Li, Maohua, et al.
Publicado: (2022)

Identification of the Ligands of TCRγδ by Screening the Immune Repertoire of γδT Cells From Patients With Tuberculosis
por: Li, Yuxia, et al.
Publicado: (2019)

Midostaurin Modulates Tumor Microenvironment and Enhances Efficacy of Anti-PD-1 against Colon Cancer
por: Lai, Cheng-Ta, et al.
Publicado: (2022)

Enhanced anti-tumor immunity of vaccine combined with anti-PD-1 antibody in a murine bladder cancer model
por: Lim, Soyeon, et al.
Publicado: (2023)

Anti-Tumor Efficacy of Anti-PD-1/PD-L1 Antibodies in Combination With Other Anticancer Drugs in Solid Tumors: A Systematic Review and Meta-Analysis
por: Inoue, Takashi, et al.
Publicado: (2022)

Classification and function of γδT cells and its research progress in anti-glioblastoma
por: Zhao, Yujuan, et al.
Publicado: (2023)

γδ T Cells Provide Protective Function in Highly Pathogenic Avian H5N1 Influenza A Virus Infection
por: Dong, Peng, et al.
Publicado: (2018)

Pectin supplement significantly enhanced the anti-PD-1 efficacy in tumor-bearing mice humanized with gut microbiota from patients with colorectal cancer
por: Zhang, Shi-Long, et al.
Publicado: (2021)

Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo
por: Rafiq, Sarwish, et al.
Publicado: (2018)

Efficacy and safety of anti-PD-1/anti-PD-L1 antibody therapy in treatment of advanced gastric cancer or gastroesophageal junction cancer: A meta-analysis
por: Yang, Li, et al.
Publicado: (2020)

Global Characterization of Differential Gene Expression Profiles in Mouse Vγ1(+) and Vγ4(+) γδ T Cells
por: Dong, Peng, et al.
Publicado: (2014)

Structural basis of the therapeutic anti-PD-L1 antibody atezolizumab
por: Zhang, Fei, et al.
Publicado: (2017)

Immunomodulatory effects of regorafenib: Enhancing the efficacy of anti-PD-1/PD-L1 therapy
por: Liu, Junjie, et al.
Publicado: (2022)

Sintilimab: A Promising Anti-Tumor PD-1 Antibody
por: Zhang, Lin, et al.
Publicado: (2020)

AntiPD-L1 antibody conjugated Au-SPIOs nanoplatform for enhancing radiosensitivity and triggering anti-tumor immune response
por: Du, Chengrun, et al.
Publicado: (2022)

Negligible heat strain in armored vehicle officers wearing personal body armor
por: Stewart, Ian B, et al.
Publicado: (2011)

Anti-PD-L1 Antibody Enhances T Cell Immune Responses and Reduces Resistance of Breast Cancer Cells to Radiotherapy
por: Guo, Lei-Ming, et al.
Publicado: (2022)

Allogenic γδ T cell and tumor cell fused vaccine for enhanced immunotherapeutic efficacy of osteosarcoma
por: Wang, Yitian, et al.
Publicado: (2018)

Anti-pancreatic tumor efficacy of a Listeria-based, Annexin A2-targeting immunotherapy in combination with anti-PD-1 antibodies
por: Kim, Victoria M., et al.
Publicado: (2019)

Synergistic anti-tumor efficacy by combination therapy of a self-assembled nanogel vaccine with an immune checkpoint anti-PD-1 antibody
por: Miura, Risako, et al.
Publicado: (2020)

Hypothalamic–Pituitary Autoimmunity in Patients Treated with Anti-PD-1 and Anti-PD-L1 Antibodies
por: Bellastella, Giuseppe, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_u339avkep58olpau60ierhccer